Sara Erridge

6.3k total citations · 2 hit papers
67 papers, 3.0k citations indexed

About

Sara Erridge is a scholar working on Pulmonary and Respiratory Medicine, Genetics and Oncology. According to data from OpenAlex, Sara Erridge has authored 67 papers receiving a total of 3.0k indexed citations (citations by other indexed papers that have themselves been cited), including 35 papers in Pulmonary and Respiratory Medicine, 33 papers in Genetics and 18 papers in Oncology. Recurrent topics in Sara Erridge's work include Glioma Diagnosis and Treatment (33 papers), Brain Metastases and Treatment (16 papers) and Lung Cancer Diagnosis and Treatment (12 papers). Sara Erridge is often cited by papers focused on Glioma Diagnosis and Treatment (33 papers), Brain Metastases and Treatment (16 papers) and Lung Cancer Diagnosis and Treatment (12 papers). Sara Erridge collaborates with scholars based in United Kingdom, Netherlands and United States. Sara Erridge's co-authors include Roger Stupp, Monika E. Hegi, Michael Weller, Matthias Preusser, Sandrine de Ribaupierre, Adelheid Wöhrer, Brigitta G. Baumert, Ian R. Whittle, Kenneth Aldape and Walter J. Curran and has published in prestigious journals such as Journal of Clinical Oncology, Neurology and Annals of Neurology.

In The Last Decade

Sara Erridge

63 papers receiving 3.0k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized Phase III Clinical Trial

2013 742 citations Mark R. Gilbert, Meihua Wang et al. Journal of Clinical Oncology profile →
ESTRO-EANO guideline on target delineation and radiotherapy details for glioblastoma

2023 90 citations Maximilian Niyazi, Nicolaus Andratschke et al. Radiotherapy and Oncology profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Sara Erridge	1.7k	990	674	652	561	67	3.0k
Jiayi Huang	969 0.6×	963 1.0×	796 1.2×	467 0.7×	620 1.1×	193	3.3k
Joshua D. Palmer	1.0k 0.6×	1.1k 1.1×	561 0.8×	387 0.6×	397 0.7×	189	2.7k
Mary Malec	1.9k 1.1×	969 1.0×	718 1.1×	645 1.0×	471 0.8×	34	3.0k
Tony J. C. Wang	858 0.5×	1.2k 1.2×	555 0.8×	440 0.7×	417 0.7×	114	2.5k
Mark G. Malkin	1.8k 1.1×	1.2k 1.2×	414 0.6×	828 1.3×	476 0.8×	71	3.2k
Steve Braunstein	891 0.5×	1.2k 1.2×	1.2k 1.8×	779 1.2×	660 1.2×	205	4.2k
Deborah T. Blumenthal	2.3k 1.4×	976 1.0×	645 1.0×	781 1.2×	560 1.0×	120	3.5k
M. Bamberg	1.1k 0.7×	1.4k 1.5×	845 1.3×	544 0.8×	465 0.8×	223	3.9k
Rakesh Jalali	1.0k 0.6×	648 0.7×	490 0.7×	286 0.4×	395 0.7×	147	2.4k
Susan Short	1.0k 0.6×	1.2k 1.2×	1.4k 2.0×	1.5k 2.3×	399 0.7×	159	4.2k

Countries citing papers authored by Sara Erridge

Since Specialization

Citations

This map shows the geographic impact of Sara Erridge's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sara Erridge with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sara Erridge more than expected).

Fields of papers citing papers by Sara Erridge

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sara Erridge. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sara Erridge. The network helps show where Sara Erridge may publish in the future.

Co-authorship network of co-authors of Sara Erridge

This figure shows the co-authorship network connecting the top 25 collaborators of Sara Erridge. A scholar is included among the top collaborators of Sara Erridge based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sara Erridge. Sara Erridge is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Rhun, Émilie Le, Sara Erridge, David A. Reardon, et al.. (2025). Proton Pump Inhibitor Use and Survival in Patients With Newly Diagnosed Glioblastoma. JAMA Network Open. 8(11). e2545578–e2545578.

Jenkinson, Michael D., Helen Bulbeck, James Burns, et al.. (2025). Seizure prophylaxis in glioma surgery (SPRING): A multi-center, unblinded, randomized trial. Neuro-Oncology Practice.

Baumert, Brigitta G., Vera C. Keil, Norbert Galldiks, et al.. (2024). ESTRO-EANO guideline on target delineation and radiotherapy for IDH-mutant WHO CNS grade 2 and 3 diffuse glioma. Radiotherapy and Oncology. 202. 110594–110594. 1 indexed citations

Williams, Sophie, Joanne Lewis, Pamela Gallagher, et al.. (2024). “It changes everything”: Understanding how people experience the impact of living with a lower-grade glioma. Neuro-Oncology Practice. 11(3). 255–265. 11 indexed citations

Jenkinson, Michael D., Helen Bulbeck, Alasdair G Rooney, et al.. (2024). P18.39.A SEIZURE PROPHYLAXIS IN GLIOMA SURGERY (SPRING): A MULTI-CENTRE, UNBLINDED, RANDOMISED TRIAL. Neuro-Oncology. 26(Supplement_5). v106–v106. 2 indexed citations

Erridge, Sara, Geoff S. Higgins, Joelle P. Straehla, et al.. (2023). Glioblastoma and the search for non-hypothesis driven combination therapeutics in academia. Frontiers in Oncology. 12. 1075559–1075559. 8 indexed citations

Niyazi, Maximilian, Nicolaus Andratschke, Martin Bendszus, et al.. (2023). ESTRO-EANO guideline on target delineation and radiotherapy details for glioblastoma. Radiotherapy and Oncology. 184. 109663–109663. 90 indexed citations breakdown →

Poon, Michael T. C., et al.. (2021). Extent of MGMT promoter methylation modifies the effect of temozolomide on overall survival in patients with glioblastoma: a regional cohort study. Neuro-Oncology Advances. 3(1). vdab171–vdab171. 10 indexed citations

Brennan, Paul M., Giles Critchley, Benjamin Hall, et al.. (2021). Second surgery for progressive glioblastoma: a multi‐centre questionnaire and cohort‐based review of clinical decision‐making and patient outcomes in current practice. Journal of Neuro-Oncology. 153(1). 99–107. 13 indexed citations

10.

Chalmers, Anthony J., Garth Cruickshank, Laurence Dunn, et al.. (2017). ACTR-16. RESULTS OF THE OPARATIC TRIAL: A PHASE I DOSE ESCALATION STUDY OF OLAPARIB IN COMBINATION WITH TEMOZOLOMIDE (TMZ) IN PATIENTS WITH RELAPSED GLIOBLASTOMA (GBM). Neuro-Oncology. 19(suppl_6). vi4–vi4. 14 indexed citations

11.

Rampling, R. & Sara Erridge. (2014). Management of Central Nervous System Tumours in The Elderly. Clinical Oncology. 26(7). 431–437. 11 indexed citations

12.

Gilbert, Mark R., Meihua Wang, Kenneth Aldape, et al.. (2013). Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized Phase III Clinical Trial. Journal of Clinical Oncology. 31(32). 4085–4091. 742 indexed citations breakdown →

13.

Rooney, Alasdair G, Shanne McNamara, Sara Erridge, et al.. (2013). Assessment of a brain-tumour-specific Patient Concerns Inventory in the neuro-oncology clinic. Supportive Care in Cancer. 22(4). 1059–1069. 26 indexed citations

14.

Stupp, Roger, Monika E. Hegi, Thierry Gorlia, et al.. (2013). Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with O⁶-methylguanine-DNA methyltransferase (MGMT) promoter methylation: Final results of the multicenter, randomized, open-label, controlled, phase III CENTRIC study.. Journal of Clinical Oncology. 31(15_suppl). LBA2009–LBA2009. 2 indexed citations

15.

Preusser, Matthias, Sandrine de Ribaupierre, Adelheid Wöhrer, et al.. (2011). Current concepts and management of glioblastoma. Annals of Neurology. 70(1). 9–21. 364 indexed citations

16.

Brada, Michael, Sally Stenning, Rhian Gabe, et al.. (2010). Temozolomide Versus Procarbazine, Lomustine, and Vincristine in Recurrent High-Grade Glioma. Journal of Clinical Oncology. 28(30). 4601–4608. 178 indexed citations

17.

Erridge, Sara, Brian Murray, Linda Williams, et al.. (2008). Improved survival from lung cancer in British Columbia compared to Scotland—Are different treatment rates the whole story?. Lung Cancer. 64(3). 358–366. 12 indexed citations

18.

Higgins, Geoff S., et al.. (2005). Myxopapillary ependymoma with intracranial metastases. British Journal of Neurosurgery. 19(4). 356–358. 12 indexed citations

19.

Erridge, Sara, Mark N. Gaze, A. Price, et al.. (2004). Symptom control and quality of life in people with lung cancer: a randomised trial of two palliative radiotherapy fractionation schedules. Clinical Oncology. 17(1). 61–67. 69 indexed citations

20.

Erridge, Sara & Nevin Murray. (2003). Thoracic radiotherapy for limited-stage small cell lung cancer: Issues of timing, volumes, dose, and fractionation. Seminars in Oncology. 30(1). 26–37. 27 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact